Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure - Wikidata - wikimedia - TriplyDB

Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure

Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure

http://www.wikidata.org/entity/Q24611940

about

Aripiprazole partial agonism at 5-HT2C: a comparison of weight gain associated with aripiprazole adjunctive to antidepressants with high versus low serotonergic activities Mechanistic relationship between the vagal afferent pathway, central nervous system and peripheral organs in appetite regulation Peripheral Serotonin: a New Player in Systemic Energy Homeostasis Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches Neural control of energy balance: translating circuits to therapies Obesity: Current and potential pharmacotherapeutics and targets.Obese and overweight children and adolescents: an algorithmic clinical approach.Bariatric endocrinology: principles of medical practice.Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?An evolving scientific basis for the prevention and treatment of pediatric obesity Characterization of the 5-HT2C receptor agonist lorcaserin on efficacy and safety measures in a rat model of diet-induced obesity.Pharmacotherapy for childhood obesity: present and future prospects.Sex difference in physical activity, energy expenditure and obesity driven by a subpopulation of hypothalamic POMC neurons.Lorcaserin for the treatment of obesity Activation of Ventral Tegmental Area 5-HT2C Receptors Reduces Incentive Motivation.Serotonergic anti-obesity agents: past experience and future prospects.Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs.Lorcaserin: a review of its use in chronic weight management.Evaluation of lorcaserin for the treatment of obesity.Novel metabolic drugs and blood pressure: implications for the treatment of obese hypertensive patients?Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs.Update on obesity pharmacotherapy.Tolerability and safety of the new anti-obesity medications.Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications.Lorcaserin for Smoking Cessation and Associated Weight Gain: A Randomized 12-Week Clinical Trial.Impact of lorcaserin on glycemic control in overweight and obese patients with type 2 diabetes: analysis of week 52 responders and nonresponders.5-hydroxytryptamine medications for the treatment of obesity.Lorcaserin Hcl for the treatment of obesity.Epidemiology of Obesity and Pharmacologic Treatment Options.A Comparison of New Pharmacological Agents for the Treatment of Obesity.Translational Modeling to Guide Study Design and Dose Choice in Obesity Exemplified by AZD1979, a Melanin-concentrating Hormone Receptor 1 Antagonist.Lorcaserin: A novel antiobesity drug.Extended calorie restriction suppresses overall and specific food cravings: a systematic review and a meta-analysis.Exploratory Literature Meta-Analysis to Characterize the Relationship Between Early and Longer Term Body Weight Loss for Antiobesity Compounds.Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials.The 5-HT₂C receptor agonist, lorcaserin, and the 5-HT₆ receptor antagonist, SB-742457, promote satiety; a microstructural analysis of feeding behaviour.Lorcaserin improves glycemic control via a melanocortin neurocircuit.Bariatric Surgery Resistance: Using Preoperative Lifestyle Medicine and/or Pharmacology for Metabolic Responsiveness.Role of impulsivity and reward in the anti-obesity actions of 5-HT2C receptor agonists.Pharmacokinetic drug evaluation of extended release lorcaserin for the treatment of obesity.

P2860

Q24615556-C206E642-0BBC-4AD4-AD1B-E4579A2021AD Q26749523-016747C6-8A51-4CC5-B0CD-7344614EA3FF Q26775537-2A1E63DE-8CB2-4342-82D5-1169341AB2C1 Q26866207-C113C668-B05B-4454-95AE-88250B097E77 Q27005992-D6E02A86-1E7C-4022-A85F-BB542A1AC99F Q30243992-7C220744-D06B-4E24-8C44-55F9EEAAAB59 Q33628264-F6A04B07-4B96-41A1-BA54-118CABA7D4C7 Q33677790-3E66ECE1-4038-4983-9841-535FAC8828AA Q33890570-EF59B955-41DA-4109-A593-7AE43D968C59 Q34028763-61D3BF95-35ED-4933-AE63-C4134DE05C29 Q35049574-C939C46D-3E6B-4AE2-85AA-B8D99A22A5E4 Q36468087-FBECBD0E-BCA2-45CC-ABD1-EFBD976ADC0D Q36628081-673C8D8E-AFF2-4A3B-975A-BA75BF322B67 Q37172259-86D078A9-047D-4F85-9520-14BDA7630394 Q37716024-E09377CA-0004-4853-B9EC-E3EA6C072542 Q37956399-E36502A0-11FF-4D5C-A837-80A6E856EFF1 Q38075153-45CAFD46-3909-4AD9-864F-B27467BE1863 Q38093129-9E44AA33-CB83-4153-8033-487B15EBB3A9 Q38117176-3E753CD1-BC00-4760-8CD5-C550BF141D5A Q38128159-16E2B350-F3FE-4963-9D73-865A20436A56 Q38167630-EC30FD9B-33D7-491A-AED0-CA920AB24D81 Q38196951-06BB4841-CA10-4DFF-88F4-2DC7344E0ECB Q38237336-4360FC6E-35ED-41D2-9D0B-64187BCF6EC2 Q38308961-0F7D9C75-16DA-4186-BE98-5BC3078EEB7D Q38385068-32A1E367-354D-4C56-83DC-BBCDCE4284C0 Q38390421-E72314D5-D4C2-4EAA-A53F-6B2C75F0DA07 Q38449992-F37F8526-A224-4E2A-BC9F-FBF211667E6C Q38608673-43AC1D3C-29E5-47B7-90E3-A03A5D57C4C7 Q38717129-8BEB0E1B-3BA8-4980-8FE4-52444F287B2B Q38737631-9C4D98C7-D922-41E1-84E3-69C96536C41A Q38757203-76037B5D-B08D-4DC4-AFCF-46ACB5C7BE89 Q39186891-15160F5C-BF03-494F-B47D-8A2E987954CF Q39338201-E5A1BB47-0A23-45EE-94CC-ABC54013D96F Q39699152-B8DD5BCA-C66B-4FDB-ACE6-181EC5C510F3 Q41653487-95CBFAA3-5F1A-420D-A6C3-1859D6E32E4D Q41910031-87322674-822C-4BB4-8C24-91126568F86F Q42377867-F1E2DE16-A34F-45A9-8130-D55EA68CCB76 Q45070738-C5FE2C68-ABF6-42BC-A9E1-0995A9FA1F56 Q47588598-717BE6E2-13EE-4B52-824F-732BA7C49CCF Q47849415-26BA8A5B-37FB-4AEC-B96C-B0D7D3DBE794

P2860

Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure

http://www.wikidata.org/entity/Q24611940

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Lorcaserin, a 5-HT(2C) recepto ...... influencing energy expenditure

@ast

Lorcaserin, a 5-HT(2C) recepto ...... influencing energy expenditure

@en

Lorcaserin, a 5-HT(2C) recepto ...... influencing energy expenditure

@nl

type

label

Lorcaserin, a 5-HT(2C) recepto ...... influencing energy expenditure

@ast

Lorcaserin, a 5-HT(2C) recepto ...... influencing energy expenditure

@en

Lorcaserin, a 5-HT(2C) recepto ...... influencing energy expenditure

@nl

prefLabel

Lorcaserin, a 5-HT(2C) recepto ...... influencing energy expenditure

@ast

Lorcaserin, a 5-HT(2C) recepto ...... influencing energy expenditure

@en

Lorcaserin, a 5-HT(2C) recepto ...... influencing energy expenditure

@nl

P1433

Q24611940-D2E553E8-4F04-43C0-916A-11BCF840523B

P1476

Q24611940-BFFC65A6-8581-4725-8E51-9C915873F2EB

P2093

Q24611940-49F2982F-1398-4789-B716-327E2A7F6434

Q24611940-6E182A06-8640-46A6-A624-E5915BF6D85F

Q24611940-7052CB68-8978-4444-96B0-5DB3416861A5

Q24611940-70AE99B3-6E96-433F-9E43-21B35A0C9168

Q24611940-B701D860-DCBF-4D86-A3F1-8547C5F026AA

Q24611940-B842F5D4-BDEB-4DBF-B34B-B0D92E6EA874

P2860

Q24611940-0A1267CE-F636-4C4B-BC52-4F13CBB4B0EB

Q24611940-1920CC67-8170-4646-B98E-3DDBA357AB8D

Q24611940-22F124B2-A32F-459A-BB38-F1849CA43733

Q24611940-27AD264E-FD49-4C20-88B8-73D521B59422

Q24611940-3F2F95CC-04AF-443C-BA71-F7A9B3F12525

Q24611940-4F5AF548-5ECD-4459-980D-15CB11E79026

Q24611940-68CD6671-90CD-4EAC-B7E5-449F4AFC482A

Q24611940-7388AACB-1193-4C6C-A79C-2E51DCB4A440

Q24611940-7CB68E5C-0EF9-4EE0-807D-B65D8F989910

Q24611940-7E73AAA4-4BFF-4529-B578-E5276D6D18F2

P304

Q24611940-D8BCC42D-C37E-46FB-BDBC-9130A6444A6B

P31

Q24611940-454819C2-8AD2-4CB2-B823-99ADCD141544

P356

Q24611940-4E1E57F4-D737-4A48-BC43-6AA0C4DCF8E0

P407

Q24611940-CACC36C2-5201-4CCA-AFEE-5D4AA5D46652

P433

Q24611940-FDE8C576-5E86-43A6-866E-C6E5E0B728B5

P478

Q24611940-A5934D25-B825-49A8-A3C2-BB856E7D556F

P50

Q24611940-758143AD-9CC4-410C-8BA6-448CF94E375D

P577

Q24611940-FAE08C15-2C16-49E7-A368-695615A0E013

P698

Q24611940-156A741A-6F6F-4542-BF55-D0846B8CC830

P921

Q24611940-517A99BD-ECF1-48CE-914F-AE3AA4B26338

Q24611940-7A835BC2-4B83-4CA7-9D9F-26A2CB1FDF03

P932

Q24611940-EAA3C148-41EE-424F-99F6-A5449A83F766

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

Lorcaserin, a 5-HT(2C) recepto ...... influencing energy expenditure

@en

P2093

Christen M Anderson

http://www.w3.org/2001/XMLSchema#string

Corby K Martin

http://www.w3.org/2001/XMLSchema#string

Jinkun Zhang

http://www.w3.org/2001/XMLSchema#string

Leanne M Redman

http://www.w3.org/2001/XMLSchema#string

Matilde Sanchez

http://www.w3.org/2001/XMLSchema#string

Steven R Smith

http://www.w3.org/2001/XMLSchema#string

P2860

Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors

Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension

Drugs and valvular heart disease

Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health

Prevalence and trends in obesity among US adults, 1999-2008

Accuracy of armband monitors for measuring daily energy expenditure in healthy adults.

Multicenter, placebo-controlled trial of lorcaserin for weight management.

Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.

Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.

P304

837-45

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2010-1848

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21190985

http://www.w3.org/2001/XMLSchema#string

P921

lorcaserin hydrochloride hemihydrate

lorcaserin hydrochloride

P932

3047218

http://www.w3.org/2001/XMLSchema#string